Navigation Links
Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
Date:11/28/2007

the businesses; unexpected costs or liabilities resulting from the transaction; the risk that synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations.

The risks included above are not exhaustive. The most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Renovis with the Securities and Exchange Commission contain additional factors that could impact the combined company's businesses and financial performance. The parties expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties' expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional information

Renovis has filed a Current Report on Form 8-K that includes as an exhibit the Agreement and Plan of Merger between Evotec and Renovis. Evotec intends to file a Registration Statement on Form F-4 with the Securities and Exchange Commission in connection with the proposed merger. Evotec and Renovis expect to mail a joint proxy statement/prospectus, which will form part of the Registration Statement on Form F-4, to shareholders of Renovis in connection with the proposed merger. This document will contain important information about the merge
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. Codexis Appoints Singapore Laboratories Managing Director
8. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 02, 2015 In the five years ... has experienced robust growth. The industry, which consists of ... energy resources and other goods, has grown on account ... As a result, IBISWorld forecasts that industry revenue will ... $946.8 million over the five-year period, including an anticipated ...
(Date:3/2/2015)... March 2, 2015 VLP Therapeutics, LLC. ... company focusing on the research and development of ... agents based upon a novel and proprietary vaccine ... Sciences Impact Grant Award from the Montgomery County ... by MCDED, is awarded to life sciences companies ...
(Date:3/2/2015)... , March 2, 2015 ... and healthy whole food nutrition products reveal technological ... lifestyle related disorders such as hyperglycemia, obesity, insulin ... concerns.  Nutraceutical and Biotech Companies in focus today ... Nature Foods Ltd. (NYSE: ANFI ), ...
(Date:3/2/2015)... SANTA BARBARA, Calif. , March 2, 2015 ... a biotechnology company developing therapies for autoimmune and ... Trademark Office (USPTO) has issued an important new ... immune system function through the targeting of CLIP. ... the targeted peptide technology underlying VG Life Sciences, ...
Breaking Biology Technology:Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 2Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 3VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development 2Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 2Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 3Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 4Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 5Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 6Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 7VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3
... ... overview of genome browsers enable researchers to quickly and effectively use these invaluable resources. ... Seattle, WA (PRWEB) April 26, ... updated tutorial suite on the Overview of Genome Browsers. , , , Ensembl is ...
... and ,S-HERTOGENBOSCH, The Netherlands , April 28, 2010 , ... technology for the generation of immune therapeutics, today,announced that it reached ... ,s-Hertogenbosch. Under the terms of the,agreement Pepscan will receive an undisclosed ... , , ...
... April 27, 2010 Immunovo,BV, a new biotechnology company looking to ... develop novel,therapeutics, secures seed funding from Dutch venture capital firms. , ... ,S-Hertogenbosch, ... new,biotechnology company developing a novel technology platform for the creation,of a new ...
Cached Biology Technology:New and Updated Online Tutorials for Ensembl Legacy and Overview of Genome Browsers 2New and Updated Online Tutorials for Ensembl Legacy and Overview of Genome Browsers 3Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 2Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 3Immunovo BV- A New Biotechnology Company is Announced 2
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... who self-paid for their antiretroviral medications experienced interruptions in ... logistical disruptions. These treatment interruptions led to the ... These findings by a team led by researchers at ... UCSF are reported in the April 22, 2007 issue ...
... College of Medicine have discovered a new way to use ... enter cancer cells. , The research appears in the Jan. ... , All living cells defend themselves by walling off the ... around the cell's inner machinery and its DNA blueprints. ...
... Autophagy is a cellular process that enables cells to ... is initiated in tumor cells by chemotherapy and radiation, ... tumor cell death or helps tumor cells survive the ... model of B cell lymphomas, researchers from the University ...
Cached Biology News:Resistance to anti-HIV drugs in Uganda developed due to drug supply problems 2Buckyballs used as 'passkey' into cancer cells 2